“Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients”
In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a standard pelvic external beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB) boost (direct insertion of radiation source over a period of minutes via flexible needles temporarily inserted in the prostate) to a shorter course of hypofractionated dose escalation radiotherapy (larger radiation dose per daily treatment) in patients with high risk prostate cancer. The investigators plan to recruit 296 patients across Quebec who will be randomized in either treatment plan.
Radiation - EBRT + HDR brachytherapy boost
Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
Radiation - Hypofractionated Dose Escalation Radiotherapy
Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
Drug - Androgen deprivation therapy
28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)